期刊文献+

乳腺癌中细胞周期素D1基因扩增和过表达及其与c-erbB-2的关系 被引量:3

Amplification and overexpression of cyclin D1 gene in breast cancer and their relations to c-erbB-2 protein
下载PDF
导出
摘要 目的 探讨细胞周期素D1基因和表达的改变在乳腺癌中的作用及其与c erbB 2表达的关系。方法 采用原位分子杂交和免疫组织化学技术检测 5 9例乳腺癌组织细胞周期素D1基因扩增、mRNA及其蛋白和c erbB 2的表达。结果  2 7例 (4 5 8% )细胞周期素D1蛋白过表达 ,其过表达与腋淋巴结转移相关 (P <0 0 5 )。细胞周期素D1DNA扩增、mRNA高表达和蛋白过表达三者基本一致 ,与c erbB 2过表达无相关。结论 细胞周期素D1蛋白过表达在乳腺癌频发 ,其基因扩增和转录增加是其重要机制之一。细胞周期素D1和c erbB 2在乳腺癌中各自发挥独立作用 。 Objective To investigate the role of the alteration of cyclin D1 gene and its expression in human breast cancer and their relations to c erbB 2 oncoprotein. Methods Cyclin D1 DNA amplification and its mRNA and protein overexpresion in 59 cases of breast cancer tissues were detected by in situ hybridization and immunohictochemical staining. C erbB 2 oncoprotein expression was detected by immunohictochemical technique, too. Result Cyclin D1 was overexpressed in 27 cases of breast cancer (45 8%), which was significantly related to lymphnode involvement ( P <0 05). Coherence was found between cyclin D1 gene amplification, its mRNA and protein overexpression. Cyclin D1 overexpression was not associated with c erbB 2 positivity. Conclusion There are frequent alterations of cyclin D1 in human breast cancer. One of the mechanisms of cyclin D1 overexpression is its DNA amplification. Cyclin D1 and c erbB 2 may play important roles independently in the development of breast cancer through different pathways. Simultaneous detection of the two proteins is helpful to evaluate prognosis of the patients.
出处 《安徽医科大学学报》 CAS 2001年第6期420-423,共4页 Acta Universitatis Medicinalis Anhui
基金 安徽省教委自然科学基金 (编号 :98jl0 6 1) 国家科技攻关地方重大项目 (编号 :99 D0 5 0 )
关键词 乳腺肿瘤 病理学 细胞周期蛋白D1 基因 erbB-2免疫组织化学 原位分子杂交 breast neoplasms/pathology cyclin D1 genes, erbB 2 gene expression immunohistochemistry hybridization, in situ
  • 相关文献

参考文献13

  • 1朱继业. 细胞生长与细胞分裂. 见:陈诗书,汤雪明主编. 医学细胞与分子生物学. 第1版, 上海:上海医科大学出版社,1995:313-330
  • 2Hirama T, Koeffler HP. Role of the cyclin-dependent kinase inhibitors in the development of cancer. Blood, 1995;86(3):841~854
  • 3Marsh KL,Varley JM. Frequent alteration of cell cycle regulators in early-stage breast lesions as detected by immunohistochemistry. Br J Cancer, 1998;77:1460~1468
  • 4Sherr CJ. Mammalian G1 cyclins. Cell, 1993;73(6):1059-1065
  • 5Gillett C, Fantl V, Smith R et al. Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res, 1994;54(7): 1812~1817
  • 6Akiyama T, Sudo C, Ogawara H et al. The product of the human c-erbB-2 gene: A 185-kilodalton glycoprotein with tyrosine kinase activity. Science,1986;232(4758):1644~1646
  • 7胡勇,饶慧蓉,吴强.癌基因c─erbB─2、抗癌基因p53在乳腺癌中表达的临床病理研究[J].临床与实验病理学杂志,1995,11(1):6-10. 被引量:41
  • 8罗玉莲,吴强.p185和p16在乳腺癌中的表达及其意义[J].安徽医科大学学报,2001,36(1):24-26. 被引量:5
  • 9Yao Y, Guan WN, Wu Q et al. Preparation of monoclonal antibody specific to c-erbB-2 gene product and biological activity in mammary cancer with immunohistochemistry method. Int J Modern Cancer Ther, 1999;2(1):58~60
  • 10Bernards R. CDK-independent activities of D type cyclins. Biochimica et Biophisica Acta, 1999; 1242(2-3): M17~M12

二级参考文献7

共引文献44

同被引文献14

  • 1刘俊茹,王原,左连富,李凤林,王莹,刘嘉琳.COX-2、p-Stat3及p-Stat5在食管癌组织中的表达及其意义[J].癌症,2007,26(5):458-462. 被引量:26
  • 2Slamon D J,Godolphin W,Jones L A,et al.Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer[J].Science,1989,244 (4905):707-12.
  • 3Hengstler J G,Lange J,Kett A,et al.Contribution of c-erbB-2 and topoisomerase Ⅱα to chemoresistance in ovarian cancer[J].Cancer Res,1999,59(13):3206-14.
  • 4Brummelkamp T R,Bernards R,Agami R.A system for stable expression of short interfering RNAs in mammalian cells[J].Science,2002,296 (5567):550-3.
  • 5Chiu Y L,Ali A,Chu C Y,et al.Visualizing a Correlation between siRNA localization,Cellular Uptake,and RNAi in Living Cells[J].Chem Biol,2004,11 (8) ;1165 -75.
  • 6Felip E,Del Campo J M,Rubio D,et al.Overexpression of cerbB-2 in epithelial ovarian cancer.Prognostic value and relationship with response to chemotherapy[J].Cancer,1995,75 (8):2147 -52.
  • 7Menendez J A,Vellon L,Lupu R.The antiobesity drug Orlistat induces cytotoxic effects,suppresses Her-2/neu (erbB-2) oncogene overexpression,and synergistically interacts with trastuzumab (Herceptin) in chemoresistant ovarian cancer cells[J].Int J Gynecol Cancer,2006,16 (1):219-21.
  • 8Brodowicz T,Wiltschke C,Budinsky A C,et al.Soluble HER-2/neu neutralizes biologic effects of anti-HER-2/neu antibody on breast cancer cells in vitro[J].Int J Cancer,1997,73 (6):875 -9.
  • 9Xu F J,Stack S,Boyer C,et al.Heregulin and agonistic antip185(c-erbB2)antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185 (c-erbB2):increased invasiveness may contribute to poor prognosis[J].Clin Cancer Res,1997,3 (9):1629-34.
  • 10Pietras R J,Fendly B M,Chazin V R,et al.Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells[J].Oncogene,1994,9 (7):1829-38.

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部